During the past decade, The Catholic University of Korea, Uijeongbu St. Mary's Hospital conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 5 clinical trials were completed, i.e. on average, 11.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 1 clinical trials were completed. i.e. 6.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" #1 sponsor was "Seung-Jung Park" with 6 trials, followed by "The Catholic University of Korea" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Uijeongbu St. Mary Hospital" with 4 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 6 trials as a collaborator, "Korean Cancer Study Group" with 3 trials as a collaborator, "Seoul National University Hospital" with 3 trials as a collaborator, "The Catholic University of Korea" with 3 trials as a collaborator and "Abbott" with 2 trials as a collaborator. Other collaborators include 61 different institutions and companies that were collaborators in the rest 60 trials.

According to Clinical.Site data, the most researched conditions in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" are "Coronary Artery Disease" (10 trials), "Atrial Fibrillation" (2 trials), "Breast Cancer" (2 trials), "Cardiovascular Disease" (2 trials) and "Hepatitis C Virus" (2 trials). Many other conditions were trialed in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" in a lesser frequency.

Most popular intervention types in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" are "Drug" (32 trials), "Device" (10 trials), "Biological" (5 trials), "Procedure" (4 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (2 trials), "bococizumab (PF-04950615)" (2 trials), "5-fluorouracil" (1 trials) and "5-fluorouracil/oxaliplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital" are 64 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Catholic University of Korea, Uijeongbu St. Mary's Hospital". undefined are not yet recruiting, 11 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in The Catholic University of Korea, Uijeongbu St. Mary's Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Catholic University of Korea, Uijeongbu St. Mary's Hospital, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 7 trials that are defined as “Not Applicable".